BACKGROUND: Sibutramine is a reuptake inhibitor of 5-hydroxytryptamine and noradrenaline, being developed as a treatment for obesity. OBJECTIVE: To investigate the effect of sibutramine on glucose homeostasis in obese-hyperglycaemic insulinresistant obaob mice. DESIGN: Sibutramine 5 mgakg once daily was administered orally to obaob mice for six weeks. RESULTS: Sibutramine treatment decreased body weight gain by 12% without a signi®cant overall change in daily food intake. Sibutramine reduced the hyperinsulinaemia by 31%, and lowered plasma non-esteri®ed fatty acids (NEFA) by 17%. Basal plasma glucose concentrations were not signi®cantly altered by sibutramine, but glucose concentrations fell more rapidly after an i.p. glucose challenge, despite lower insulin concentrations. The rate of insulin-induced glucose disappearance was increased by 10% during sibutramine treatment. First administration of sibutramine, 5 mgakg, did not acutely alter basal plasma glucose, insulin or NEFA concentrations in obaob mice, although NEFA concentrations were raised after 24 h. CONCLUSION: The results indicate that chronic administration of sibutramine can reduce weight gain, lower NEFA concentrations, decrease hyperinsulinaemia and ameliorate the insulin resistance of obaob mice.
Introduction
Sibutramine (BTS 54524; N-[1-[1-(4-chlorophenyl)-cyclobutyl]-3-methylbutyl]-N,N-dimethylamine hydrochloride monohydrate; Figure 1 ) is a 5-hydroxy tryptamine (5-HT) and noradrenaline reuptake inhibitor, which has been shown to reduce body weight gain in laboratory rodents and promote weight loss in obese humans. 1±3 In rodents, sibutramine causes a dose-dependent suppression of food intake due to an increased post-ingestive satiety response, 4 and elevated energy expenditure through enhanced thermogenesis. 5 In obese non-insulin dependent diabetic patients receiving sibutramine, the reduction in weight was accompanied by improved glucose tolerance. 6, 7 The present study examines the effect of sibutramine on the development of obesity and impaired glucose homeostasis in hyperphagic, obese-diabetic, leptin-defective obaob mice. 8, 9 The study provides evidence that chronic sibutramine treatment can reduce weight gain and ameliorate the hyperinsulinaemia and insulin resistance in these mice, at a dosage which does not signi®cantly alter the overall daily consumption of food.
Methods
Obese-hyperglycaemic obaob mice from the Aston colony (Birmingham, UK) were used. The origin and characteristics of these mice have been described previously. 10, 11 Mice were housed in groups of 3± 4 per cage, maintained at 22 AE 2 C with a ®xed 12 h light ± dark cycle (08.00 ±22.00 h light), and supplied a standard pellet diet (Economy Rodent Breeder Diet, SDS, Witham, Essex) and tap water.
Chronic effect of sibutramine
Two groups of obaob mice aged ®ve weeks were initially matched for body weight and basal plasma glucose concentration. After a one week run-in period, the test group received sibutramine hydrochloride (Knoll Pharmaceuticals, Nottingham, UK; 5 mga kgad) given by oral gavage at 17.00 h, and the placebo control group received vehicle only (phosphate buffered saline, 2.5 mlakgad). Treatment was continued for six weeks, and the mice were monitored for a further four weeks after treatment was stopped. Food and drinking water were available ad libitum, and food consumption and body weight were measured daily. 12 Mean daily food intake per mouse was calculated using the daily measurements from two cages over a period of one week. Blood samples (100 ml) were taken at weekly intervals from the tail tip at 11.00 h. Plasma was separated and stored until assayed for glucose, 13 non-esteri®ed fatty acids (NEFA; enzymatic colorimetric kit, Wako Chemicals, Neuss, Germany), and insulin (Amerlex magnetic separation method, Amersham Life Science, Amersham, UK) using rat insulin as standard.
An i.p. glucose tolerance test was conducted at 11.00 h in non-fasted mice after ®ve weeks of treatment. Blood samples for plasma glucose and insulin assay were taken immediately before and 30, 60 and 120 min after administration of glucose (2 gakg, i.p., in a 40% wav solution). Food was withheld during the test. An insulin hypoglycaemia test was also conducted after ®ve weeks of treatment, and again four weeks after treatment was stopped. Blood samples for plasma glucose assay were taken immediately before and 30, 60 and 120 mins after i.p. administration of human insulin (Actrapid, Novo Nordisk, Crawley, UK; 2.5 uakg), and food was withheld during the test. The initial rate of plasma glucose disappearance was taken as the percentage decrease in plasma glucose from time zero to 30 mins.
Acute effect of sibutramine
Groups of obaob mice aged 12 weeks were matched for body weight and basal plasma glucose concentrations. Either sibutramine hydrochloride (5 mgakg) or placebo control (phosphate buffered saline, 2.5 mlakg) was administered by oral gavage at 10.00 h. Blood samples for plasma glucose, insulin and NEFA assay were taken from the tail tip immediately before and 2, 4, 8 and 24 h after drug administration. Food was withheld for 0 ±8 h, then mice were permitted to feed ad libitum for 8±24 h, and the amount of food consumed was noted. In a separate experiment, an insulin hypoglycaemia test (as above) was conducted at 24 h.
Statistical analysis
Results are presented as mean AE s.e.m. Data were analysed by one-way ANOVA and Student's t-tests. Differences were considered to be signi®cant if P`0.05.
Results

Chronic effect of sibutramine
The placebo treated obaob mice were characteristically obese, hyperphagic and hyperinsulinaemic, with modestly raised plasma concentrations of glucose and NEFA ( Figure 2 ). Administration of sibutramine (5 mgakgad, orally) for six weeks reduced body weight gain by about 8 g (12%, P`0.05), although mean daily food intake was not signi®cantly altered (8.3 AE 0.3 and 8.6AE 0.4 gamousead in the sibutramine and placebo groups, respectively). Basal plasma glucose concentrations were also unaltered by sibutramine, but signi®cant reductions (P`0.05) in the plasma concentrations of insulin and NEFA were observed after four weeks and two weeks, respectively ( Figure 2 ). Compared with placebo treatment, the mean plasma insulin concentration was 31% lower during sibutramine treatment (9.1AE 1.0 vs 13.3 AE Figure 2 Body weight, food intake and plasma concentrations of glucose, insulin and non-esteri®ed fatty acids (NEFA) in obaob mice during and after treatment with sibutramine 5 mgakgad) for six weeks. s---s placebo-treated; dÐd sibutramine-treated. Values are mean AE s.e.m., n 7. *P`0.05 vs placebo.
Effects of sibutramine in obaob mice C Day and CJ Bailey 1.7 ngaml; P`0.05), and the mean plasma NEFA concentration was 17% lower during sibutramine treatment (1.34 AE 0.07 vs 1.63AE 0.11 mmolal, P`0.05). An i.p. glucose tolerance test conducted after ®ve weeks of sibutramine treatment (Figure 3 ), showed a 23% lower plasma glucose concentration by 120 min (P`0.05) and a 17% lower mean AUC value (2709AE 181 vs 3296 AE 234 mmolal.120 min, P0
.075, not statistically signi®cant (NS)). Typical of fed adult obaob mice, there was no immediate insulin response to an i.p. glucose challenge in the placebo group.
14 However, the sibutramine group, which showed lower basal insulin concentrations, responded to the glucose challenge with a prompt increase in insulin concentrations (almost 3-fold, P`0.01) between 0 ±30 min ( Figure 3 ). Insulin concentrations then declined to less than half those of the placebo group by 120 min (P`0.05). The concurrently reduced plasma concentrations of insulin and glucose by 120 min, signify a decrease in insulin resistance.
Insulin sensitivity, assessed by an insulin hypoglycaemia test, was improved after ®ve weeks of sibutramine treatment (Figure 4 ). The rate of plasma glucose disappearance was 10% faster after sibutramine (decrease in plasma glucose 0 ±30 min was 56.1 AE 3.9% after sibutramine vs 45.4AE 2.8% for placebo; P`0.05).
When sibutramine treatment was stopped, there was only a gradual and partial`catch-up' in body weight gain over four weeks. Mean daily food intake was slightly (but not signi®cantly) higher in the ex-sibutramine group than the placebo group (8.5AE 0.4 vs 8.1 AE 0.4 gamousead). However, plasma concentrations of insulin and NEFA returned to placebo values within 1±2 weeks of stopping sibutramine (Figure 2 ). An insulin hypoglycaemia test conducted four weeks after stopping sibutramine treatment, was similar to the placebo (decrease in plasma glucose 0 ±30 min was 25.3 AE 6.9% ex-sibutramine and 33.2 AE 5.9% in the placebo group, respectively). The slower rates of glucose disappearance in both groups illustrate the age-related escalation of insulin resistance in obaob mice ( Figure 5 ).
Acute effect of sibutramine
To investigate a possible acute effect of sibutramine, groups of mice were studied at intervals over 24 h, after an oral dosage of 5 mgakg ( Figure 6 ). There were no signi®cant effects on plasma glucose, insulin and NEFA concentrations during the 0 ±8 h period when food was withheld. Food intake (8 ±24 h) was 16% lower after sibutramine than placebo (7.3AE 0.2 vs Effects of sibutramine in obaob mice C Day and CJ Bailey 8.8 AE 0.2 gamouse, P`0.01), and NEFA concentrations were higher at 24 h. An insulin hypoglycaemia test conducted at 24 h showed no signi®cant difference in the rate of plasma glucose disappearance (28.7 AE 1.9% and 25.3 AE 3.4% for sibutramine and placebo, respectively).
Discussion
This study has shown that the anti-obesity agent sibutramine (5 mgakgad) reduced body weight gain in obese-diabetic obaob mice. This occurred without a signi®cant chronic change in food intake. Since the drug produced an acute satiety-inducing effect in the obaob mice, as noted in other rodents, 4 ,5 it appears that such an effect may not be maintained during chronic treatment. Indeed, a recent study in obese faafa rats noted that sibutramine (10 mgakgad) only reduced food intake during the ®rst week of treatment, but reduced body weight gain thereafter without a signi®cant decrease in food intake. 5 In obaob mice, several agents which are acutely anorexigenic have been shown to have little effect on overall daily food intake during chronic administration. 12, 15 The obaob mice quickly compensate over a daily feeding cycle for an acute energy de®cit. 16 Thus the chronic maintenance of overall daily food intake may disguise adjustments to the pattern of feeding; for example, eating discrete meals can alter the daily pro®le of insulin concentrations, reduce insulin resistance and improve nutrient homeostasis in these mice. 16 Use of selective antagonists has indicated that the acute satiety-inducing effect of sibutramine involves a 1 and b 1 adrenoceptors as well as 5-HT 2C and possibly 5-HT 2A receptors. 17 Since neither sibutramine nor its two amine metabolites exhibit af®nity for a 1 , b 1 or 5-HT receptors, the drug appears to enhance monoaminergic function by inhibiting noradrenaline and 5-HT reuptake. 1 It is not known whether sibutramine affects the neuropeptide Y (NPY) pathway controlling feeding and adiposity, 18 as postulated for leptin, 19 but the lack of a substantive or sustained decrease in food intake, suggests that this is unlikely to be a major mechanism for the chronic effect of sibutramine on body weight in this study.
The chronic suppression of body weight gain by sibutramine has mainly been attributed to increased energy expenditure, as illustrated by increased oxygen consumption and thermogenesis in faafa rats. 5 This is due at least in part to sympathetic stimulation of thermogenesis by brown adipose tissue, mediated via the action of noradrenaline on b 3 adrenoceptors. 20 Body fat mass was not measured in this study, but sibutramine caused mainly loss of adipose tissue in obese humans. 21 Consistent with the known association between obesity, insulin resistance and diabetes, 22 the weight loss was associated with improved glucose homeostasis in these patients. 7 Using obese-diabetic obaob mice, this study has demonstrated that chronic administration of sibutramine reduced hyperinsulinaemia and increased insulin-mediated glucose disposal, indicating an amelioration of insulin resistance. The extent to which these effects result from reduced adiposity and altered feeding behaviour cannot be assessed from the experimental design, but it appears that sibutramine can also act independently to in¯uence metabolic parameters. For example, when sibutramine was stopped, the plasma NEFA and insulin concentrations quickly returned to placebo values, but only a small amount of weight was regained and only very slowly.
Whereas chronic treatment with 5 mgakgad sibutramine lowered the glucose concentration 2 h after an i.p. glucose challenge (Figure 3) , basal glycaemia was not reduced during either chronic treatment or acutely (0 ±8 h) after ®rst administration of this dosage of sibutramine. Unlike chronic treatment, which decreased plasma NEFA concentrations, there was a rise in plasma NEFA 24 h after ®rst administration. While this is consistent with the initial decrease in food intake, it might also represent an initial Figure 6 Plasma concentrations of glucose, insulin and nonesteri®ed fatty acids (NEFA) in obaob mice during 24 h after ®rst administration of sibutramine (5 mgakg). Food was withheld during 0±8 h, and mice were fed ad libitum for 8±24 h, during this time sibutramine-treated and placebo-treated groups consumed 7.3 AE 0.2 and 8.8 AE 0.2 gamouse, respectively (P`09.01). s---s placebo-treated; dÐd sibutramine-treated. Values are mean AE s.e.m., n 6, *P`0.05 vs placebo.
Effects of sibutramine in obaob mice C Day and CJ Bailey mobilization of adipose tissue, which levels out during chronic treatment in accordance with a reduced adipose mass. A gradual gain in body weight after stopping sibutramine contrasts with the rapid compensation or over-compensation, seen after stopping treatment with various anorexigenic and sympathomimetic agents in obaob mice, 23, 24 suggesting fundamental differences in the weight-lowering action of sibutramine. Thus the present study demonstrates that sibutramine can reduce weight-gain in obaob mice at a dosage 5 mgakgad which does not cause a signi®cant chronic reduction in food intake. The sibutramine treatment lowered NEFA concentrations, reduced the hyperinsulinaemia and decreased the insulin resistance of obaob mice.
